vs

Side-by-side financial comparison of EXACT SCIENCES CORP (EXAS) and KIRBY CORP (KEX). Click either name above to swap in a different company.

EXACT SCIENCES CORP is the larger business by last-quarter revenue ($878.4M vs $851.8M, roughly 1.0× KIRBY CORP). KIRBY CORP runs the higher net margin — 10.8% vs -9.8%, a 20.6% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 6.2%). KIRBY CORP produced more free cash flow last quarter ($265.2M vs $120.4M). Over the past eight quarters, EXACT SCIENCES CORP's revenue compounded faster (17.4% CAGR vs 2.7%).

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

Kirby Corporation, headquartered in Houston, Texas, is the largest tank barge operator in the United States, transporting bulk liquid products throughout the Mississippi River System, on the Gulf Intracoastal Waterway, along all three U.S. Coasts, and in Alaska and Hawaii. Products transported by Kirby include petrochemicals, black oil, refined petroleum products, and agricultural chemical products by tank barge. Kirby also owns and operates eight ocean-going barge and tug units transporting ...

EXAS vs KEX — Head-to-Head

Bigger by revenue
EXAS
EXAS
1.0× larger
EXAS
$878.4M
$851.8M
KEX
Growing faster (revenue YoY)
EXAS
EXAS
+17.0% gap
EXAS
23.1%
6.2%
KEX
Higher net margin
KEX
KEX
20.6% more per $
KEX
10.8%
-9.8%
EXAS
More free cash flow
KEX
KEX
$144.7M more FCF
KEX
$265.2M
$120.4M
EXAS
Faster 2-yr revenue CAGR
EXAS
EXAS
Annualised
EXAS
17.4%
2.7%
KEX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EXAS
EXAS
KEX
KEX
Revenue
$878.4M
$851.8M
Net Profit
$-86.0M
$91.8M
Gross Margin
70.1%
Operating Margin
-9.4%
15.2%
Net Margin
-9.8%
10.8%
Revenue YoY
23.1%
6.2%
Net Profit YoY
90.1%
114.4%
EPS (diluted)
$-0.45
$1.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXAS
EXAS
KEX
KEX
Q4 25
$878.4M
$851.8M
Q3 25
$850.7M
$871.2M
Q2 25
$811.1M
$855.5M
Q1 25
$706.8M
$785.7M
Q4 24
$713.4M
$802.3M
Q3 24
$708.7M
$831.1M
Q2 24
$699.3M
$824.4M
Q1 24
$637.5M
$808.0M
Net Profit
EXAS
EXAS
KEX
KEX
Q4 25
$-86.0M
$91.8M
Q3 25
$-19.6M
$92.5M
Q2 25
$-1.2M
$94.3M
Q1 25
$-101.2M
$76.0M
Q4 24
$-864.6M
$42.8M
Q3 24
$-38.2M
$90.0M
Q2 24
$-15.8M
$83.9M
Q1 24
$-110.2M
$70.1M
Gross Margin
EXAS
EXAS
KEX
KEX
Q4 25
70.1%
Q3 25
68.6%
Q2 25
69.3%
Q1 25
70.8%
Q4 24
69.0%
Q3 24
69.4%
Q2 24
69.8%
Q1 24
70.0%
Operating Margin
EXAS
EXAS
KEX
KEX
Q4 25
-9.4%
15.2%
Q3 25
-3.0%
14.8%
Q2 25
-0.3%
15.4%
Q1 25
-13.6%
13.4%
Q4 24
-122.8%
6.3%
Q3 24
-5.6%
15.3%
Q2 24
-3.8%
14.6%
Q1 24
-16.7%
12.6%
Net Margin
EXAS
EXAS
KEX
KEX
Q4 25
-9.8%
10.8%
Q3 25
-2.3%
10.6%
Q2 25
-0.1%
11.0%
Q1 25
-14.3%
9.7%
Q4 24
-121.2%
5.3%
Q3 24
-5.4%
10.8%
Q2 24
-2.3%
10.2%
Q1 24
-17.3%
8.7%
EPS (diluted)
EXAS
EXAS
KEX
KEX
Q4 25
$-0.45
$1.68
Q3 25
$-0.10
$1.65
Q2 25
$-0.01
$1.67
Q1 25
$-0.54
$1.33
Q4 24
$-4.69
$0.74
Q3 24
$-0.21
$1.55
Q2 24
$-0.09
$1.43
Q1 24
$-0.60
$1.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXAS
EXAS
KEX
KEX
Cash + ST InvestmentsLiquidity on hand
$964.7M
$78.8M
Total DebtLower is stronger
$919.3M
Stockholders' EquityBook value
$2.4B
$3.4B
Total Assets
$5.9B
$6.0B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXAS
EXAS
KEX
KEX
Q4 25
$964.7M
$78.8M
Q3 25
$1.0B
$47.0M
Q2 25
$858.4M
$68.4M
Q1 25
$786.2M
$51.1M
Q4 24
$1.0B
$74.4M
Q3 24
$1.0B
$67.1M
Q2 24
$946.8M
$53.5M
Q1 24
$652.1M
$75.2M
Total Debt
EXAS
EXAS
KEX
KEX
Q4 25
$919.3M
Q3 25
$1.0B
Q2 25
$1.1B
Q1 25
$1.1B
Q4 24
$874.9M
Q3 24
$978.6M
Q2 24
$1.0B
Q1 24
$1.1B
Stockholders' Equity
EXAS
EXAS
KEX
KEX
Q4 25
$2.4B
$3.4B
Q3 25
$2.5B
$3.4B
Q2 25
$2.5B
$3.4B
Q1 25
$2.4B
$3.3B
Q4 24
$2.4B
$3.4B
Q3 24
$3.2B
$3.3B
Q2 24
$3.2B
$3.3B
Q1 24
$3.1B
$3.2B
Total Assets
EXAS
EXAS
KEX
KEX
Q4 25
$5.9B
$6.0B
Q3 25
$5.9B
$6.1B
Q2 25
$5.8B
$6.1B
Q1 25
$5.7B
$6.0B
Q4 24
$5.9B
$5.9B
Q3 24
$6.7B
$5.9B
Q2 24
$6.7B
$5.9B
Q1 24
$6.4B
$5.8B
Debt / Equity
EXAS
EXAS
KEX
KEX
Q4 25
0.27×
Q3 25
0.31×
Q2 25
0.33×
Q1 25
0.33×
Q4 24
0.26×
Q3 24
0.30×
Q2 24
0.32×
Q1 24
0.33×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXAS
EXAS
KEX
KEX
Operating Cash FlowLast quarter
$151.7M
$312.2M
Free Cash FlowOCF − Capex
$120.4M
$265.2M
FCF MarginFCF / Revenue
13.7%
31.1%
Capex IntensityCapex / Revenue
3.6%
5.5%
Cash ConversionOCF / Net Profit
3.40×
TTM Free Cash FlowTrailing 4 quarters
$356.8M
$405.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXAS
EXAS
KEX
KEX
Q4 25
$151.7M
$312.2M
Q3 25
$219.9M
$227.5M
Q2 25
$89.0M
$93.9M
Q1 25
$30.8M
$36.5M
Q4 24
$47.1M
$247.4M
Q3 24
$138.7M
$206.5M
Q2 24
$107.1M
$179.3M
Q1 24
$-82.3M
$123.3M
Free Cash Flow
EXAS
EXAS
KEX
KEX
Q4 25
$120.4M
$265.2M
Q3 25
$190.0M
$160.3M
Q2 25
$46.7M
$22.4M
Q1 25
$-365.0K
$-42.1M
Q4 24
$10.7M
$150.7M
Q3 24
$112.6M
$130.1M
Q2 24
$71.2M
$90.8M
Q1 24
$-120.0M
$42.2M
FCF Margin
EXAS
EXAS
KEX
KEX
Q4 25
13.7%
31.1%
Q3 25
22.3%
18.4%
Q2 25
5.8%
2.6%
Q1 25
-0.1%
-5.4%
Q4 24
1.5%
18.8%
Q3 24
15.9%
15.7%
Q2 24
10.2%
11.0%
Q1 24
-18.8%
5.2%
Capex Intensity
EXAS
EXAS
KEX
KEX
Q4 25
3.6%
5.5%
Q3 25
3.5%
7.7%
Q2 25
5.2%
8.4%
Q1 25
4.4%
10.0%
Q4 24
5.1%
12.0%
Q3 24
3.7%
9.2%
Q2 24
5.1%
10.7%
Q1 24
5.9%
10.0%
Cash Conversion
EXAS
EXAS
KEX
KEX
Q4 25
3.40×
Q3 25
2.46×
Q2 25
1.00×
Q1 25
0.48×
Q4 24
5.78×
Q3 24
2.30×
Q2 24
2.14×
Q1 24
1.76×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXAS
EXAS

Screening$695.1M79%
Precision Oncology$183.2M21%

KEX
KEX

Inland Transportation$379.2M45%
Power Generation$191.1M22%
Commercial And Industrial$149.4M18%
Coastal Transportation$102.5M12%
Oil And Gas$29.6M3%

Related Comparisons